• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Medtronic plc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    6/23/25 4:17:20 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MDT alert in real time by email
    mdt-20250618
    0001613103H91 VY19false00016131032025-06-182025-06-180001613103us-gaap:CommonStockMember2025-06-182025-06-180001613103mdt:A0.250SeniorNotesDue2025Member2025-06-182025-06-180001613103mdt:A0.000SeniorNotesDue2025Member2025-06-182025-06-180001613103mdt:A2.625SeniorNotesDue2025Member2025-06-182025-06-180001613103mdt:A1.125SeniorNotesDue2027Member2025-06-182025-06-180001613103mdt:A0.375SeniorNotesDue2028Member2025-06-182025-06-180001613103mdt:A3.000SeniorNotesDue2028Member2025-06-182025-06-180001613103mdt:A3.650SeniorNotesDue2029Member2025-06-182025-06-180001613103mdt:A1.625SeniorNotesDue2031Member2025-06-182025-06-180001613103mdt:A1.000SeniorNotesDue2031Member2025-06-182025-06-180001613103mdt:A3.125SeniorNotesDue2031Member2025-06-182025-06-180001613103mdt:A0.750SeniorNotesDue2032Member2025-06-182025-06-180001613103mdt:A3.375SeniorNotesDue2034Member2025-06-182025-06-180001613103mdt:A3.875SeniorNotesDue2036Member2025-06-182025-06-180001613103mdt:A2.250SeniorNotesDue2039Member2025-06-182025-06-180001613103mdt:A1.500SeniorNotesDue2039Member2025-06-182025-06-180001613103mdt:A1.375SeniorNotesDue2040Member2025-06-182025-06-180001613103mdt:A4.150SeniorNotesDue2043Member2025-06-182025-06-180001613103mdt:A1.750SeniorNotesDue2049Member2025-06-182025-06-180001613103mdt:A1.625SeniorNotesDue2050Member2025-06-182025-06-180001613103mdt:A4.150SeniorNotesDue2053Member2025-06-182025-06-18

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    _____________________________ 
    FORM 8-K
     _____________________________ 
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of
    the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): June 18, 2025
     _____________________________ 
    Medtronic plc
    (Exact name of Registrant as Specified in its Charter)
      _____________________________ 
     
    Ireland 1-36820 98-1183488
    (State or other jurisdiction
    of incorporation)
     
    (Commission
    File Number)
     
    (IRS Employer
    Identification No.)

    Building Two
    Parkmore Business Park West
    Galway, Ireland
    (Address of principal executive offices) (Zip Code)
    +353 1 438-1700
    (Registrant’s telephone number, including area code)
    Not Applicable
    Former name or former address, if changed since last report
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))













    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading SymbolName of each exchange on which registered
    Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange
    0.250% Senior Notes due 2025MDT/25New York Stock Exchange
    0.000% Senior Notes due 2025MDT/25ANew York Stock Exchange
    2.625% Senior Notes due 2025MDT/25BNew York Stock Exchange
    1.125% Senior Notes due 2027MDT/27New York Stock Exchange
    0.375% Senior Notes due 2028MDT/28New York Stock Exchange
    3.000% Senior Notes due 2028MDT/28ANew York Stock Exchange
    3.650% Senior Notes due 2029MDT/29New York Stock Exchange
    1.625% Senior Notes due 2031MDT/31New York Stock Exchange
    1.000% Senior Notes due 2031MDT/31ANew York Stock Exchange
    3.125% Senior Notes due 2031MDT/31BNew York Stock Exchange
    0.750% Senior Notes due 2032MDT/32New York Stock Exchange
    3.375% Senior Notes due 2034MDT/34New York Stock Exchange
    3.875% Senior Notes due 2036MDT/36New York Stock Exchange
    2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange
    1.500% Senior Notes due 2039MDT/39BNew York Stock Exchange
    1.375% Senior Notes due 2040MDT/40ANew York Stock Exchange
    4.150% Senior Notes due 2043MDT/43ANew York Stock Exchange
    1.750% Senior Notes due 2049MDT/49New York Stock Exchange
    1.625% Senior Notes due 2050MDT/50New York Stock Exchange
    4.150% Senior Notes due 2053MDT/53New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





    Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
    On June 18, 2025, the Board of Directors (Board) of Medtronic plc (Company) increased the size of the Board from 10 to 11 and appointed Dr. Joon Lee as a new director of the Company, in each case effective as of June 18, 2025. Dr. Lee has been appointed to serve on the Science and Technology Committee and the Compensation and Talent Committee of the Board.
    In connection with his appointment to the Board, pursuant to the Company’s non-employee director compensation policy, Dr. Lee will be eligible to receive an annual cash retainer and a director equity grant, in each case as described under “Corporate Governance—Director Compensation” in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on August 9, 2024.
    There were no arrangements or understandings between Dr. Lee and any other persons pursuant to which he was selected as a director, and neither Dr. Lee nor any of his immediate family has been a party to any transaction or currently proposed transaction with the Company that is reportable under Item 404(a) of Regulation S-K.
    A press release announcing Dr. Lee’s appointment was issued on June 23, 2025. A copy of such press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

    Item 9.01.Exhibits.
    (d) List of Exhibits
    Exhibit Number  Description
    99.1
      
    Press release of Medtronic plc, dated June 23, 2025.
    104
    Cover Page Interactive Data File (embedded with the Inline XBRL document).










    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
       Medtronic plc
      By /s/ Ivan K. Fong
    Date: June 23, 2025   Ivan K. Fong
       Executive Vice President, General Counsel and Secretary






    EXHIBIT INDEX
    Exhibit Number  Description
    99.1
      
    Press release of Medtronic plc, dated June 23, 2025.
    104
    Cover Page Interactive Data File (embedded with the Inline XBRL document).

    Get the next $MDT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MDT

    DatePrice TargetRatingAnalyst
    6/30/2025Underperform → Peer Perform
    Wolfe Research
    6/16/2025$110.00Outperform
    Leerink Partners
    3/4/2025$92.00 → $107.00Neutral → Buy
    Citigroup
    10/10/2024$98.00 → $105.00Sector Perform → Outperform
    RBC Capital Mkts
    8/21/2024$92.00 → $94.00Perform
    Oppenheimer
    8/15/2024$76.00 → $90.00Sell → Neutral
    UBS
    8/14/2024$100.00 → $85.00Buy → Hold
    Stifel
    5/30/2024$83.00Sell
    Goldman
    More analyst ratings

    $MDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Medtronic upgraded by Wolfe Research

      Wolfe Research upgraded Medtronic from Underperform to Peer Perform

      6/30/25 7:56:30 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Leerink Partners initiated coverage on Medtronic with a new price target

      Leerink Partners initiated coverage of Medtronic with a rating of Outperform and set a new price target of $110.00

      6/16/25 7:51:25 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic upgraded by Citigroup with a new price target

      Citigroup upgraded Medtronic from Neutral to Buy and set a new price target of $107.00 from $92.00 previously

      3/4/25 7:37:34 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MDT
    Leadership Updates

    Live Leadership Updates

    See more
    • Medtronic announces appointment of MiniMed chief financial officer ahead of intended separation into standalone company

      GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to become fully independent.  Chad brings over 25 years of financial leadership experience across healthcare, consumer, and industrial sectors. Most recently, he served as CFO at BIC (BB:PA), a pu

      7/8/25 8:45:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic Board appoints Dr. Joon Lee as a new director

      GALWAY, Ireland, June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent director, effective June 18, 2025. Dr. Lee will serve on the Science and Technology Committee and Compensation and Talent Committee of the Board. "We are thrilled to welcome Dr. Lee, a highly respected interventional cardiologist and healthcare executive, to Medtronic's Board of Directors," said Geoff Martha, chairman and chief executive officer. "Dr. Lee brings deep expertise as a clinical researcher, academic leader, and physician executive with dec

      6/23/25 4:15:00 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

      NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

      3/31/25 4:21:30 PM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products

    $MDT
    Financials

    Live finance-specific insights

    See more
    • Medtronic announces cash dividend for fourth quarter of fiscal year 2025

      GALWAY, Ireland, March 6, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 6, 2025, approved the company's cash dividend for the fourth quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on April 11, 2025, to shareholders of record at the close of business on March 28, 2025. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquart

      3/6/25 4:30:00 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic reports third quarter fiscal 2025 financial results

      Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation GALWAY, Ireland, Feb. 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025. Key Highlights Revenue of $8.3 billion increased 2.5% as reported and 4.1% organicGAAP diluted EPS of $1.01 increased 2%; non-GAAP diluted EPS of $1.39 increased 7%Company reiterates full year revenue and EPS guidanceCardiac Ablation Solutions revenue increased low-20s on strength of pulsed field ablation (PFA) productsU.S. Centers for Medicare and Medic

      2/18/25 6:45:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic announces cash dividend for third quarter of fiscal year 2025

      GALWAY, Ireland, Dec. 5, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 5, 2024, approved the company's cash dividend for the third quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on January 10, 2025, to shareholders of record at the close of business on December 27, 2024. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, hea

      12/5/24 4:30:00 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

      SC 13G/A - Medtronic plc (0001613103) (Subject)

      2/13/24 5:09:43 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

      SC 13G/A - Medtronic plc (0001613103) (Subject)

      2/12/24 1:59:55 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

      SC 13G/A - Medtronic plc (0001613103) (Subject)

      2/15/23 3:34:14 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MDT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Medtronic secures CE Mark for MiniMed™ 780G System for insulin-requiring people with diabetes including expanded indications in children as young as two, during pregnancy, and for type 2 diabetes

      GALWAY, Ireland, July 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in medical technology, today announced CE (Conformité Européenne) Mark in Europe to expand indications of the MiniMed™ 780G system for use by individuals aged 2 years and older, during pregnancy, as well as type 2 insulin-requiring diabetes. To gain CE Mark for this expansion of indications, published clinical data in 2–6-year-olds, pregnant women, and people living with type 2 diabetes was reviewed. This expanded indication underscores the commitment Medtronic has to advancing access to automated insulin delivery (AID) technology for broader and more diverse populations, helping to improve outcomes and

      7/21/25 8:45:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Watts Water Technologies Names Ryan Lada as Chief Financial Officer

      Watts Water Technologies, Inc. (NYSE:WTS) today announced that Ryan Lada has been appointed Chief Financial Officer effective July 28, 2025. Mr. Lada succeeds current Chief Financial Officer Shashank Patel, who previously announced his intent to retire in October 2024. Mr. Lada joins Watts from The AZEK Company, where he most recently served as Senior Vice President, Chief Financial Officer and Treasurer and was responsible for overseeing AZEK's enterprise-wide financial operations, overall financial and capital allocation strategy, and investor relations efforts. Mr. Lada departed AZEK on July 11, 2025 following its acquisition by James Hardie Industries. Chief Executive Officer, Presi

      7/14/25 9:00:00 AM ET
      $GE
      $IEX
      $MDT
      $WTS
      Consumer Electronics/Appliances
      Technology
      Fluid Controls
      Industrials
    • Medtronic announces appointment of MiniMed chief financial officer ahead of intended separation into standalone company

      GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to become fully independent.  Chad brings over 25 years of financial leadership experience across healthcare, consumer, and industrial sectors. Most recently, he served as CFO at BIC (BB:PA), a pu

      7/8/25 8:45:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Lee Joon Sup claimed no ownership of stock in the company (SEC Form 3)

      3 - Medtronic plc (0001613103) (Issuer)

      7/2/25 4:36:21 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Accounting Officer Blomquist Denise L. gifted 310 units of Ordinary Shares, decreasing direct ownership by 3% to 10,143 units (SEC Form 4)

      4 - Medtronic plc (0001613103) (Issuer)

      6/4/25 4:30:34 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • New insider Kiil Harry Skip claimed ownership of 33,442 units of Ordinary Shares (SEC Form 3)

      3 - Medtronic plc (0001613103) (Issuer)

      6/4/25 4:29:12 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MDT
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Medtronic plc.

      25-NSE - Medtronic plc (0001613103) (Subject)

      7/2/25 1:17:58 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic plc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Medtronic plc (0001613103) (Filer)

      6/23/25 4:17:20 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form IRANNOTICE filed by Medtronic plc.

      IRANNOTICE - Medtronic plc (0001613103) (Filer)

      6/20/25 6:46:40 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care